• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global Biopharma Outlook 2012 - Rising Stars and Mature Biotech Product Image

Global Biopharma Outlook 2012 - Rising Stars and Mature Biotech

  • Published: January 2012
  • Region: Global
  • 130 Pages
  • MP Advisors

FEATURED COMPANIES

  • Ablynx
  • Amarin
  • ArQule
  • Galapagos
  • Intercell
  • MorphoSys
  • MORE

Global Biopharma Outlook 2012: Rising stars and Mature Biotech

The Rising Stars (non-profitable biotech/ biopharma companies) chapter reiterates that Innovation and improvements will continue to flow from the backyards of small research focused companies. There is likely to be a Paradigm shift in investment pattern- choosing upside from early mid-stage products and not from to launches. 2012 will be a testing time for recently approved drugs as many of the innovators have taken the responsibility of selling the drug in US on their own (REGN, INCY, VRTX etc)- Will they evolve into a mature biotech or remain a shining star only? In-depth analyses of specific companies, investment recommendation valuations are included

MP Advisors' definition of Mature Biotech (MB)- companies which have reached sustainable profitability by generating revenues from product/s innovated, developed and generally commercialized in house. Robust earning from majority of the companies cheered investors. Restructuring, cash return to shareholder in form of dividends and share buyback along with promise to create further value sustained optimism in 2011. These companies are – entering 2012 READ MORE >

Global Biopharma Outlook 2012: Rising Stars
Macro Analysis

- Top Picks for 2012
- MP's Performance for 2011
- Paradigm shift in investing pattern: Tap Them Young
- Innovation Rewarded- Drug approvals in 2011 and Expected Drug Launch in 2012
- Many Up For Garage Sale but Technology Platforms will Continue to Attract
Top Picks - Company Analyses
- Anthera Pharma
- Incyte
- Micromet
Other Outperform Recommendations - Company Analyses
- Ardea Biosciences
- ArQule
- Immunomedics
- MorphoSys
- Regeneron
- Vertex
Market Perform Recommendations – Company Analyses
- Amarin
- AVEO Pharma
- Galapagos
- ISIS Pharma
- Medivir
- Rigel Pharma
Not Rated – Company Analyses
- Ablynx
- Allos Therapeutics
- Alnylam Pharma
- Intercell
- Protalix
Rising Stars Sector Industry Tables
Annexure 1: Drug Clinical Milestones
Annexure 2: Drug Launch Table - 2012
Annexure 3: Npv Valuation

Global Biopharma Outlook 2012: Mature Biotech
Macro Analysis
- Top Picks for 2012
- MP's Performance in 2011
- Boosting R&D Productivity Through Smart Acquisitions
- Key Milestones Through 2012-13
- Relative Valuation amidst Modest Generic Challenges

Top Picks - Company Analyses
-Biogen Idec
-Gilead
Other Outperform Recommendations – Company Analyses
-Alexion
-Amgen
-Celgene
Market Perform Recommendation – Company Analysis
-Onyx Pharma
Mature Biotech Sector Industry Tables

- Biogen Idec
- Gilead
- Alexion
- Amgen
- Celgene
- Onyx Pharma
- Anthera Pharma
- Incyte
- Micromet
- Ardea Biosciences
- ArQule
- Immunomedics
- MorphoSys
- Regeneron
- Vertex
- Amarin
- AVEO Pharma
- Galapagos
- ISIS Pharma
- Medivir
- Rigel Pharma
- Ablynx
- Allos Therapeutics
- Alnylam Pharma
- Intercell
- Protalix

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos